1
项与 HIV 1 antigen expanded specific T cell(University of North Carolina) 相关的临床试验IGHID 11627 - A Phase I Study to Evaluate the Effects of Vorinostat and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on Persistent HIV-1 Infection in HIV-Infected Individuals Started on Antiretroviral Therapy (The XTRA Study)
This is a phase I, single-site, study to evaluate the effects of VOR and HIV-1 Antigen Expanded Specific T Cell Therapy (HXTC) on persistent HIV-1 Infection in HIV-infected individuals suppressed on ART. Twelve participants with durable viral suppression will be enrolled and will complete the study. All participants will receive the same treatment and if eligible, will be dosed with HXTC and VOR. Participants will continue their baseline ART regimen throughout the study.
100 项与 HIV 1 antigen expanded specific T cell(University of North Carolina) 相关的临床结果
100 项与 HIV 1 antigen expanded specific T cell(University of North Carolina) 相关的转化医学
100 项与 HIV 1 antigen expanded specific T cell(University of North Carolina) 相关的专利(医药)
100 项与 HIV 1 antigen expanded specific T cell(University of North Carolina) 相关的药物交易